Search: onr:"swepub:oai:prod.swepub.kib.ki.se:1946348" >
Venlafaxine extende...
Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study
-
- Allgulander, C (author)
- Karolinska Institutet
-
Hackett, D (author)
-
Salinas, E (author)
-
(creator_code:org_t)
- 2018-01-02
- 2001
- English.
-
In: The British journal of psychiatry : the journal of mental science. - : Royal College of Psychiatrists. - 0007-1250. ; 179, s. 15-22
- Related links:
-
https://www.cambridg...
-
show more...
-
http://kipublication...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment.AimsTo assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD.MethodA total of 541 out-patients, 18–86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER.ResultsAll doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups.ConclusionsVenlafaxine ER is an effective and safe treatment for GAD for up to 6 months.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database